Implications of ASGPR in Disease Development (P42187)

Target Name: Asialoglycoprotein Receptor (ASGPR)

NCBI ID: P42187

Asialoglycoprotein Receptor (ASGPR)

Other Name(s): ASGPR | Asialoglycoprotein Receptor

Implications of ASGPR in Disease Development

Asialoglycoprotein Receptor (ASGPR), also known as ASGPR or ALRP1, is a protein that is expressed in various tissues throughout the body. It is a member of the tyrosine kinase family and is involved in the regulation of cellular processes such as cell signaling, inflammation , and fibrosis. The ASGPR gene has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

ASGPR is a transmembrane protein that is expressed in the cell surface. It consists of an extracellular portion, a transmembrane region, and an intracellular portion. The extracellular portion of ASGPR is involved in its cell surface localization and interactions with other proteins. is responsible for the protein's ability to interact with intracellular signaling molecules. The intracellular portion of ASGPR is involved in the regulation of cellular processes such as cell signaling, DNA replication, and apoptosis.

ASGPR has been shown to play a role in the development and progression of various diseases. For example, it has been implicated in the development of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Studies have shown that ASGPR is expressed in the brains of individuals with these conditions and that its levels are decreased in the brains of individuals with these conditions compared to age-matched controls. This suggests that ASGPR may be a potential drug target or biomarker for these diseases.

ASGPR has also been shown to be involved in the regulation of cell signaling. Many signaling pathways in the cell involve the regulation of protein levels, including the regulation of ASGPR. For example, the PI3K/Akt signaling pathway is involved in the regulation of ASGPR levels and has been shown to be involved in the development and progression of various diseases. Studies have shown that individuals with certain genetic mutations, such as those in the PI3K gene, are at increased risk for the development of certain diseases. This suggests that ASGPR may be a potential drug target or biomarker for these diseases.

ASGPR has also been shown to be involved in the regulation of DNA replication. Studies have shown that ASGPR is involved in the regulation of DNA replication in various cell types. This suggests that ASGPR may be a potential drug target or biomarker for diseases that involve DNA replication, such as cancer.

ASGPR has also been shown to be involved in the regulation of apoptosis. Apoptosis is a process that is involved in the regulation of cell life cycle and has been implicated in the development and progression of various diseases. Studies have shown that ASGPR is involved in the regulation of apoptosis in various cell types. This suggests that ASGPR may be a potential drug target or biomarker for diseases that involve apoptosis.

In conclusion, ASGPR is a protein that is involved in the regulation of various cellular processes and has been implicated in the development and progression of various diseases. As a potential drug target or biomarker, ASGPR may be a valuable tool for the development of new therapies for these diseases. Further research is needed to fully understand the role of ASGPR in the regulation of cellular processes and its potential as a drug target or biomarker.

Protein Name: Asialoglycoprotein Receptor (ASGPR) (nonspecified Subtype)

The "Asialoglycoprotein Receptor (ASGPR) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Asialoglycoprotein Receptor (ASGPR) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets